HHS Carcinogen Report Updated to Include 8 Substances
The US Department of HHS added 8 new substances to the 15th Report on Carcinogens, bringing the total list to 256 substances.
Poisoning
BP Control Lower for Current Smokers, Especially Men
Rates of BP control lower for current smokers; 45.5 percent of men had blood pressure >180 and/or >100 mm Hg
FDA Authorizes First E-Cigarette
Antismoking advocates say the authorization ‘leaves our nation’s youth at an undue risk of addiction’
Once-Weekly Levomethadone Fast Tracked for Opioid Use Disorder
LYN-014 is an investigational oral, once-weekly, ultra-long-acting, extended-release levomethadone capsule to treat opioid use disorder.
Risk of Falsely Low Results Prompts Recall of Lead Tests
The FDA is concerned that obtaining falsely low test results may lead to inappropriate follow-up assessments, which may result in patient harm.
FDA to Review Buprenorphine Extended-Release Injection for Opioid Use Disorder
Brixadi (buprenorphine) is an investigational, extended-release weekly and monthly subcutaneous injection for moderate to severe opioid use disorder.
Guidelines Developed for Diagnosing, Treating Botulism
Signs and symptoms of some neurologic conditions overlap with botulism; thorough, serial neurologic exams should be conducted.
Anavip Approval Expanded to Include Copperhead, Cottonmouth/Water Moccasin Envenomations
Anavip contains venom-specific F(ab’)2 fragments of immunoglobulin G that bind and neutralize venom toxins.
Shortage of Lead Poisoning Treatment Announced
Chemet is an orally active, heavy metal chelating agent indicated for the treatment of lead poisoning in pediatric patients.
CDC: ~20% of US Adults Currently Use Tobacco Products
Prevalence of use higher for men, adults aged ≤65 years, uninsured, those with disability or limitation
